Drug Testing and Analysis
July 1, 2011
Leslie A. King, Andrew T. Kicman
99 citations
This special issue of DTA is devoted to what were once known as 'designer drugs', but in recent times have been described informally as 'legal highs'. The preferred term, as adopted by the European Community in 2005[1], [2] is 'new psychoactive substances'. They are defined as 'Narcotic or psychotropic drugs that are not scheduled under the United Nations 1961 or 1971 Conventions, but which may...
Annals of the New York Academy of Sciences
June 1, 2002
John K. Fallon, Dhwanil Shah, Andrew T. Kicman et al.
54 citations
A bstract : 3,4‐Methylenedioxymethamphetamine (MDMA) has been reported to cause hyponatraemia, which appears to result from inappropriate secretion of the antidiuretic hormone arginine vasopressin (AVP). After administration of a low dose of ( R,S )‐MDMA (40 mg) to eight healthy drug‐free male volunteers, concentrations of AVP in plasma increased significantly at 1, 2, and 4 hours. Although no...
British Journal of Pharmacology
February 1, 2002
Mary L. Forsling, John K. Fallon, Darshna Shah et al.
77 citations
Methylenedioxymethamphetamine (MDMA, “ecstasy”), widely used as a recreational drug, can produce hyponatraemia. The possibility that this could result from stimulation of vasopressin by MDMA or one of its metabolites has been investigated in vitro . Release of both oxytocin and vasopressin from isolated hypothalami obtained from male Wistar rats was determined under basal conditions and...
Clinical Chemistry
July 1, 1999
John K. Fallon, Andrew T. Kicman, J. A. Henry et al.
137 citations
Abstract Background: Little is known concerning the enantioselective disposition of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) in humans. In addition, the potential of utilizing the stereochemical composition of an analyte in biological media for forensic purposes requires investigation. Methods: The enantiomers of MDMA and its demethylated metabolite, 3,4-methylenedioxyamphetamine...